Braidwell LP Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Braidwell LP purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 623,980 shares of the company’s stock, valued at approximately $3,020,000. Braidwell LP owned approximately 0.74% of Verve Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of VERV. Nisa Investment Advisors LLC increased its position in shares of Verve Therapeutics by 908.4% in the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after acquiring an additional 6,949 shares in the last quarter. Creative Planning purchased a new position in Verve Therapeutics during the 3rd quarter worth approximately $50,000. PFG Investments LLC purchased a new position in Verve Therapeutics during the 3rd quarter worth approximately $53,000. Daiwa Securities Group Inc. raised its stake in Verve Therapeutics by 89.8% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after purchasing an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. boosted its position in shares of Verve Therapeutics by 13.5% in the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after buying an additional 1,778 shares during the period. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Trading Up 8.9 %

Shares of NASDAQ:VERV opened at $5.78 on Friday. The business has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $5.60. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The company had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business’s quarterly revenue was up 120.2% on a year-over-year basis. During the same period last year, the business earned ($0.72) EPS. Analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on VERV shares. Royal Bank of Canada dropped their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright reduced their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.